Assignee
LEVETAN CLARESA
US·10 granted patents·14 pending applications·38 citations·filing 2012–2024
Top patents by PatentIndex Score
24 records- 0193US9321812B2Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptideLEVETAN CLARESA·Filed 2014·Granted Apr 26, 2016·7 cites·16 claims
- 0291US10016482B2Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptideLEVETAN CLARESA·Filed 2016·Granted Jul 10, 2018·3 cites·3 claims
- 0391US10010580B2Insulin independence among patients with diabetes utilizing an optimized hamster Reg3 gamma peptideLEVETAN CLARESA·Filed 2016·Granted Jul 3, 2018·3 cites·3 claims
- 0491US10010577B2Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptideLEVETAN CLARESA·Filed 2016·Granted Jul 3, 2018·3 cites·3 claims
- 0589US10010578B2Insulin independence among patients with diabetes utilizing an optimized hamster Reg3 gamma peptideLEVETAN CLARESA·Filed 2016·Granted Jul 3, 2018·3 cites·3 claims
- 0689US9511110B2Generation of new pancreatic beta cellsLEVETAN CLARESA·Filed 2012·Granted Dec 6, 2016·6 cites·15 claims
- 0786US10010579B2Insulin independence among patients with diabetes utilizing an optimized hamster Reg3 gamma peptideLEVETAN CLARESA·Filed 2016·Granted Jul 3, 2018·3 cites·3 claims
- 0886US8911776B2Generation of new pancreatic beta cellsLEVETAN CLARESA·Filed 2012·Granted Dec 16, 2014·4 cites·13 claims
- 0982US9133440B2Generation of new pancreatic beta cellsLEVETAN CLARESA·Filed 2012·Granted Sep 15, 2015·3 cites·10 claims
- 1082US8808689B1Insulin independence among patients with diabetes utilizing a PPI in combination with an immune tolerance agentLEVETAN CLARESA·Filed 2013·Granted Aug 19, 2014·3 cites·14 claims
- 1170US2018125933A1Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptideLEVETAN CLARESA·Filed 2017·Application pending·0 cites
- 1266US2025099544A1Treatment of Type 1 Diabetes and Other Conditions Using the Gut MicrobiomeLEVETAN CLARESA·Filed 2024·Application pending·0 cites
- 1365US2020054716A1Compositions and methods for treating or preventing type 1 diabetes using a biologic response modifier in combination with one or more islet or beta cell regeneration or replacement therapiesLEVETAN CLARESA·Filed 2019·Application pending·0 cites
- 1459US2014235552A1Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agentLEVETAN CLARESA·Filed 2013·Application pending·0 cites
- 1558US2019142901A1Compositions and methods for treating or preventing type 1 diabetes using a biologic response modifier in combination with one or more islet or beta cell regeneration or replacement therapiesLEVETAN CLARESA·Filed 2017·Application pending·0 cites
- 1656US2021371478A1Generation of brain and spinal cord neurons, cardiac myocytes, and hepatocytes using reg peptides, peptidomimetics, small molecules and stimulatory antibodies to reg receptorLEVETAN CLARESA·Filed 2021·Application pending·0 cites
- 1752US2019328839A1Treatment of Type 1 Diabetes and Other Conditions Using the Gut MicrobiomeLEVETAN CLARESA·Filed 2019·Application pending·0 cites
- 1851US2021299226A1Method of treating and preventing coronaviruses with low dosage interferon beta-1a as a th17 inhibitorLEVETAN CLARESA·Filed 2020·Application pending·0 cites
- 1951US2015174111A1Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agentLEVETAN CLARESA·Filed 2015·Application pending·0 cites
- 2050US2014234405A1Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agentLEVETAN CLARESA·Filed 2013·Application pending·0 cites
- 2146US2019330289A1Generation of brain and spinal cord neurons, cardiac myocytes, renal nephrons and hepatocytes using reg peptides, peptidomimetics, small molecules and stimulatory antibodies to reg receptorLEVETAN CLARESA·Filed 2019·Application pending·0 cites
- 2244US2014120560A1Generation of new pancreatic beta cellsLEVETAN CLARESA·Filed 2012·Application pending·0 cites
- 2342US2013216545A1Early Diagnosis and Novel Treatment of CancerLEVETAN CLARESA·Filed 2012·Application pending·0 cites
- 2441US2017081375A1Generation of brain and spinal cord neurons, cardiac myocytes, renal nephrons and hepatocytes using reg peptides, peptidomimetics, small molecules and stimulatory antibodies to reg receptorLEVETAN CLARESA·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when LEVETAN CLARESA files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →